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Objective: To be utilized for the development of pharmacists’ intervention service by determining factors which
affect pharmacists’ prescription interventions.
Setting: Patients who were admitted to intensive care units (ICUs) in internal medicine departments in Korea.
Methods: Data including age, gender, clinical departments, length of hospital stay, status of organ dysfunction,
intervention status, frequently intervened drugs, and health care providers’ questions were prospectively collected
in ICUs in the department of internal medicine in a tertiary teaching hospital from January to December, 2012.
Main outcome measure: Primary outcome was factors which affect pharmacists’ prescription interventions.
Secondary outcomes included frequencies of the intervention, intervention acceptance rates, intervention issues,
and frequently intervened drugs.
Results: A total of 1,213 prescription interventions were made for 445 patients (33.1%) of the 1,344 patients that
were analyzed. Length of hospital stay was significantly longer for the group that needed pharmacists’ interventions
(p < 0.001). Pharmacists’ intervention requirements were significantly higher in patients with kidney dysfunction
(p < 0.001). The percentage of intervention accepted was 96.8%, and interventions that were common were as
follows (in order): clinical pharmacokinetic service, dosage or dosing interval changes, dosing time changes or dose
changes, and total parenteral nutrition consultation. The five medications with the highest intervened frequency
were (in order) vancomycin, famotidine, ranitidine, meropenem, and theophylline.
Conclusion: The need for pharmacists’ prescription interventions was highest among patients with longer length
of stay and patients with kidney dysfunction. Based on these findings, prescription intervention activities could be
initiated with severely ill patients. The results could be utilized in countries which are planning to develop
pharmacists’ intervention service.
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Major activities of hospital pharmacists in countries with
advanced clinical pharmacies, such as the U.S, can be
summarized as ones that provide safe medication adminis-
tration to patients. In those countries, clinical pharmacists
have historically performed prescription interventions in
fulfilling their clinical duties as part of health care team.
Many studies have reported that such activities contribute
greatly patient safety and appropriate medication use* Correspondence: hsgwak@ewha.ac.kr; bklee@ewha.ac.kr
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Attribution License (http://creativecommons.or
in any medium, provided the original work is pbringing about economic benefits (Gillespie et al. 2009;
Saokaew et al. 2009; Kopp et al. 2007; Scarsi et al. 2002;
Devlin et al. 1997).
In contrast, in Asia and other developing countries, due
to the lack of awareness of the role of or the need for clin-
ical pharmacists, clinical activities of hospital pharmacists
are not as encouraged as in the U.S. (Khalili et al. 2011;
Nissen 2009). This situation is the same in Korea in which
clinical pharmacists’ role in hospital pharmacy has a
greater emphasis on dispensing and drug distribution
and a relatively smaller emphasis on clinical pharmacy
interventions.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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2000 in Korea with the separation of dispensing and pre-
scribing functions, which led to the widespread use of
aseptic preparations of injectable drugs, the expansion of
the use of unit doses, and the more widespread use of
daily preparation system. Although it is true that large
variations exist among hospitals, major hospitals provide
pharmacy services that are comparable to those in coun-
tries such as drug information services, clinical pharma-
cokinetic consultation services, the development of
specialized medication counseling, and the operation of
services tailored to the needs of specific patients in clin-
ical divisions.
Samsung Medical Center, in which the present study was
conducted, is one of the major five hospitals in Korea, con-
sisting of a main hospital and a cancer treatment hospital.
The main hospital has 1,900 beds, and the cancer treatment
hospital has over 600 inpatient beds, and both hospitals
have ICUs. The hospital founded the first ‘Department of
Critical Care Medicine’ in Korea in March 2013, which is
an independent medical department for ICUs.
The pharmacy in this study began a clinical service for
15 bed Medical ICU unit in February 17, 2009 by creating
a team consisting of one clinical pharmacist and the ICU
medical staff. Based on a positive feedback on clinical
pharmacist’s activities of one year period in 2010, two clin-
ical pharmacists became in charge of a full-scale ICU ser-
vice in the department of internal medicine in the main
hospital and the cancer treatment hospital (a total of 30
beds) (Figure 1). In March, 2013, the department of crit-
ical care medicine (CCM) was established. At the request
of the CCM department, patients in the departments of
general surgery, division of cardiology, thoracic surgery,
and general surgery in the cancer treatment hospital were
added to the scope of patients receiving such services, and
currently, there are a total of four pharmacists in charge of
ICU patients. The ICU pharmacists are clinical pharma-
cists licensed by the U.S. Board of Pharmacy Specialties
(BPS) or by the Korean Board of Pharmaceutical Special-
ties and have more than five years of work experience.Figure 1 Intervention service of intensive care unit pharmacists. MICU
CCU: coronary care unit, TSICU: trauma surgical intensive care unit.They follow the Fundamental, Desirable, Optimal Critical
Care Pharmacist Activities Guidelines stated in the Pos-
ition Paper on Critical Care Pharmacy Services created by
American College of Clinical Pharmacy (ACCP) and the
Society of Critical Care Medicine (SCCM) (2000).
They perform medication profile management, prescrip-
tion intervention activity, ADR monitoring, and thera-
peutic drug monitoring (TDM) work, as well as TPN
consultation referrals and participate in the nutrition sup-
port team (NST) rounds. In addition, they provide infor-
mation on new drugs and pharmaceuticals of interest.
Other clinical pharmacist activities include providing in-
formation on changes in drug supply and medication dis-
pensing as well as providing insurance-related information
and performing education for health care professionals.
ICU patients in particular have a high risk and a high
frequency of adverse drug reactions (ADR) when prescrip-
tion errors occur (Leape 1997). This is due to their critical
condition, multi-drug use, and the continuing changes in
their pharmacokinetic parameters. Thus, a plethora of re-
search has reported that pharmacists’ participation in the
pharmacological treatment of ICU patients can lower the
frequency of prescription errors or ADRs, and improve
treatment outcomes including reduction of length of hos-
pital stay (Saokaew et al. 2009; Kaushal et al. 2008; Kane
et al. 2003; Calabrese et al. 2001; Kaboli et al. 2006). How-
ever, no particular study on this topic has been conducted
in Korea.
Aim of study
The study aim was to develop pharmacist intervention
service by examining factors affecting pharmacists’ pre-
scription interventions, issues with interventions, and
the effect of prescription intervention activities, thereby,
being utilized for the development of pharmacists’ inter-
vention service.
Method
The present study was prospectively conducted on pa-
tients who were admitted to ICUs in a tertiary teaching: medical intensive care unit, SICU: surgical intensive care unit,
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collected were age, gender, Simplified Acute Physiology
Score (SAPS) III, clinical departments, length of hospital
stay, type of organ dysfunction (kidney or liver dysfunction),
intervention status, and frequently intervened drugs. All
prescriptions were checked for drug choice appropriate-
ness, dose and dose reductions according to organ dysfunc-
tions, administration routes, compatibilities, indications,
interactions, and adverse drug reactions. Renal dysfunc-
tion was defined as the creatinine clearance less than
50 mL/min. Hepatic dysfunction was defined as the aspar-
tate aminotransferase or alanine aminotransferase ≥ nor-
mal value × 3. For the primary outcomes, factors affecting
pharmacist interventions were evaluated. With respect to
the secondary outcomes, the followings were obtained: the
number of interventions, intervention acceptance rates,
intervention issues, frequently intervened drugs.
Continuous variables were compared by the Student’s t-
test. If the variables were not normally distributed, as deter-
mined by the one-sample Kolmogorov-Smirnov, additional
Mann–Whitney tests were used. The Chi-square or Fisher’s
exact test was used to compare categorical variables. A
multiple regression model was used to investigate the fac-
tors that independently affected the pharmacist interven-
tion. The data were analyzed using Statistical Package for
Social Sciences Version 12.0 for Windows (SPSS INC.,
Chicago, IL, USA). A P-value of less than 0.05 was consid-
ered statistically significant.
Ethical approval
This study was conducted with the approval of the insti-
tutional review board (IRB) of Samsung Medical Center
(IRB # 2012-07-117).
Results
During the study period, the number of patients who were
admitted to the ICU at the department of internal medi-
cine was 1,344, and the number of patients who needed
pharmacists’ interventions was 445 (33.1%). A total of
1,213 interventions were performed for the 445 patients
(Figure 2). The average values of SAPS III was 55.7 in the
main hospital patients and 62.8 in the cancer treatment
hospital patients.
As shown in Table 1, there was no significant difference
in age and sex between patients with and without pharma-
cist interventions. The relationship between the type of
clinical departments and the number of pharmacist inter-
ventions was significant (p < 0.001), with the division of
gastroenterology having a lower rate of patients in need of
intervention than other divisions. In contrast, the divisions
of pulmonary and hematology/oncology, showed a higher
rate of patients in need of intervention compared to the
other departments. In the length of hospital stay, the
group in need of clinical pharmacist interventions hadsignificantly longer hospital stay than the other group (p <
0.001). The need for intervention was influenced by the
presence of kidney dysfunction (p < 0.001), so patients
with kidney dysfunction required more clinical pharmacist
intervention than patients without kidney dysfunction
(Table 1).
The results of the multivariable analysis on the variables
whose significance level was less than 0.1 in Table 1, ex-
cept for the clinical departments due to the possible multi-
colinearity problem, showed that the odds of belonging to
the intervention group increased 1.160 times with a 1 day
increase in the length of hospital stay (95% CI, 1.134–
1.186). The significantly higher likelihood (OR 1.759, 95%
CI, 1.340–2.309) to need pharmacist interventions was
found in patients with kidney dysfunction (Table 2).
A total of 1,213 interventions were made for 445 pa-
tients among the 1,344 participating patients who were
admitted to ICUs during the one year study period, and
the frequency was the highest for patients with one inter-
vention (47.4%). As for the intervention acceptance rate,
in a total of 1,212 interventions except for one missing
case out of 1,213, 1,173 interventions (96.8%) were ac-
cepted. The results of intervention issues showed that sig-
nificant differences existed in acceptance rates depending
on intervention issues (p = 0.001). Table 3 showed that the
acceptance rate for interventions for medication change
was 80.0%, which was lower than the average acceptance
rate of 96.8%. The intervention issue with the highest fre-
quency was clinical pharmacokinetic service with 286 in-
terventions, followed by dosage decrement/dosing interval
increment with 243 interventions, dosing time or dose
with 212 interventions, and TPN consultation with 114 in-
terventions. Thus, the issues related to drug dose (dose,
dosing interval, and dosing time).
Table 4 shows intervention issues for the top five
drugs (vancomycin, famotidine, ranitidine, meropenem,
theophylline) with the highest number of interventions,
indicating significantly different intervention issues de-
pending on the drug. For vancomycin and theophylline,
the clinical pharmacokinetic service was the most inter-
vened issues. On the contrary, for famotidine, ranitidine,
and meropenem, the rates of dosage decreases and dos-
ing interval increases were higher than 50%. The overall
frequencies of prescriptions of vancomycin, famotidine,
ranitidine, meropenem, and theophylline were 1467,
1018, 1105, 1438, and 403, respectively.
Discussion
The intervention was conducted to 445 patients out of
1,344 study populations, which was 33.1%. Other studies
showed various intervention rates; one study showed 12
out of 50 ICU patients whereas another study reported
much higher intervention rate of 47% (Devlin et al. 1997;
Khalili et al. 2013).
Figure 2 Study profile of clinical pharmacist interventions.
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first, cases without an error in the doctor’s prescription;
second, temporary admissions to ICUs for continuous
renal replacement therapy; and third, cases that did not
need additional dose adjustment such as patients without
organ dysfunction. The third group accounted for a signifi-
cant portion of no intervention requirement, therefore, the
cases in which patients had organ dysfunction such as kid-
ney dysfunction became mostly the target of intervention.
The result of the relationship between the number of
interventions and the type of clinical departments wasTable 1 Patient characteristics according to the presence and
Total (n = 1,344








Hematology & Oncology 521
Infectious Diseases 98
Others 79
Length of hospital stay, median (range), day1 4.0 (1–195)







1Two patients who were staying in hospital at the point of data collection were excsignificant (p < 0.001), with the division of hematology &
oncology and pulmonary having the highest intervention
rate, and the division of gastroenterology having a lower
rate of patients. Most patients with a respiratory disease
had diseases such as sepsis, pneumonia, and acute re-
spiratory distress syndrome, which are conditions that
usually require medications that need dose adjustment
such as antibiotics, sedatives, analgesics, and steroids.
On the other hand, the division of gastroenterology did not
need many pharmacist interventions, although there are a
large number of patients with liver disease. In the case ofabsence of pharmacist intervention requirements
) Required pharmacist intervention P-value
Yes (n = 445) No (n = 899)
64.0 (18–94) 64.0 (10–95) 0.648
0.367
291 (65.4) 565 (62.8)
154 (34.6) 334 (37.2)
<0.001
19 (4.3) 120 (13.3)
164 (36.9) 259 (28.8)
19 (4.3) 65 (7.2)
189 (42.5) 332 (36.9)
31 (7.0) 67 (7.5)
23 (5.2) 56 (6.2)
9.0 (1–195) 2.0 (1–109) <0.001
<0.001
173 (38.9) 246 (27.4)
272 (61.1) 653 (72.6)
0.062
62 (13.9) 163 (18.1)
383 (86.1) 736 (81.9)
luded.
Table 2 Factors associated with pharmacist interventions
OR (95% CI)a P-value
Length of hospital stay, day 1.160 (1.134–1.186) <0.001
Renal dysfunction
No 1 -
Yes 1.759 (1.340–2.309) <0.001
Hepatic dysfunction
No 1 -
Yes 0.918 (0.639–1.318) 0.642
OR, odds ratio; CI, confidence interval. aAdjusted for length of hospital stay,
renal dysfunction, and hepatic dysfunction.
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pharmacist intervention are due to relatively low number
of medications administered for treatment, fewer dose ad-
justment guidelines for liver dysfunction compared with
kidney dysfunction, and the already established protocols
in the clinical department with respect to drug treatment.
In clinical conditions, the percentage of patients with
renal dysfunction was higher among patients requiring
pharmacist’s interventions compared to those without
pharmacist’s intervention requirement. Therefore, kid-
ney function is considered to be correlated directly with
greater pharmacists’ interventions.
There were 246 patients with renal failure in the group
without intervention although the portion was significantly




Dosing Dosage decrement or dosing interval increment
Dosing time or dose
Dosage increment or dosing interval decrement
Dosing route










Values are expressed as the number (percentage).
1Composed of drug omission 10 cases, prescription check 6 cases, and close monito
P-value = 0.001.that a significant portion of no intervention requirement
was the cases in which patients had kidney dysfunction was
because adjusted drug dosing was initiated to patients with
severely impaired renal function.
In Kane et al.’s review, the issues that require additional
attention included dose adjustment for decreased kidney
and liver function, prevention and monitoring of ADRs,
drug interactions caused by complex drug regimens, nutri-
tional assessment due to poor oral intake and change in
calorie needs, compatibility checks due to a patient’s ex-
tensive list of intravenous medications, and treatment and
prevention of life-threatening infections, which are the
same as the intervention issues encountered in the present
study (Kane et al. 2003).
Hospital stay was found to be significantly longer for the
group needing pharmacist interventions (p < 0.01). It can
be interpreted that patients with longer hospital stay are
more likely to need pharmacist’ proactive intervention be-
cause of the higher probability of severe illness among
these patients, with many complications or delayed treat-
ment in this group.
As for the acceptance rate of intervention, among the
total of 1,212 evaluated interventions excluding 1 missing
case, 1,173 cases were accepted (96.8%). This result was
comparable to the 96.5% acceptance rate in the study by
Vessal et al. (Vessal 2010). The main reason for the non-
acceptance was prescription change or cancellation due to
the alteration of patient health status.Total (n = 1,212) Acceptance of Intervention
Yes (n = 1,173) No (n = 39)
286 (100.0) 282 (98.6) 4 (1.4)
114 (100.0) 107 (93.9) 7 (6.1)
243 (100.0) 232 (95.5) 11 (4.5)
212 (100.0) 208 (98.1) 4 (1.9)
92 (100.0) 90 (97.8) 2 (2.2)
19 (100.0) 19 (100.0) 0 (0.0)
47 (100.0) 45 (95.7) 2 (4.3)
20 (100.0) 19 (95.0) 1 (5.0)
20 (100.0) 16 (80.0) 4 (20.0)
16 (100.0) 16 (100.0) 0 (0.0)
79 (100.0) 78 (98.7) 1 (1.3)
17 (100.0) 17 (100.0) 0 (0.0)
15 (100.0) 13 (86.7) 2 (13.3)
13 (100.0) 12 (92.3) 1 (7.7)
19 (100.0) 19 (100.0)1 0 (0.0)
1,212 (100.0) 1,173 (96.8) 39 (3.2)
ring recommendation 3 cases.
Table 4 Intervention issues of top five medications
Medication Vancomycin Famotidine Ranitidine Meropenem Theophylline
Intervention Issue
Clinical pharmacokinetic service 201 (85.2) 0 (0.0) 0 (0.0) 0 (0.0) 20 (47.6)
Dosage increment or dosing interval decrement 5 (2.1) 4 (6.5) 2 (3.4) 13 (22.8) 5 (11.9)
Dosage decrement or dosing interval increment 8 (3.4) 42 (67.7) 36 (62.1) 32 (56.1) 1 (2.4)
Medication form 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.4)
Dosing time or dose 19 (8.1) 4 (6.5) 5 (8.6) 8 (14.0) 10 (23.8)
Dosing route 1 (0.4) 3 (4.8) 1 (1.7) 0 (0.0) 1 (2.4)
Discontinuation of medication 0 (0.0) 3 (4.8) 2 (3.4) 0 (0.0) 1 (2.4)
Medication change 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0)
Adverse drug reaction 1 (0.4) 5 (8.1) 11 (19.0) 2 (3.5) 1 (2.4)
Fluid compatibility 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 0 (0.0)
Drug interaction 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 1 (2.4)
Others 0 (0.0) 0 (0.0) 1 (1.7)1 0 (0.0) 1 (2.4)
Total 236 (100.0) 62 (100.0) 58 (100.0) 57 (100.0) 42 (100.0)
Values are expressed as the number (percentage).
1Drug Omission.
P-value < 0.001.
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ities in ICUs have a positive effect in the patient safety, as
illustrated by Calabrese et al. who reported that medica-
tion error was reduced by 3.3% with routine activities of
clinical pharmacists in ICUs. Other studies showed that
25% of inappropriate drug concentrations were prevented
by therapeutic drug monitoring, ADE decreased by 66%,
and a potential estimated annual cost saving of 270,000
US dollars (Kane et al. 2003; Calabrese et al. 2001; Dager
and Alberson 1992; Leape et al. 1999).
Although this study is not sufficient to prove the effect-
iveness of clinical pharmacists’ activities in ICUs, pharma-
cists in charge of ICU patients have already taken on a
role as an important member of the health care team in
ICUs. As a result, the number of dedicated pharmacist
doubled; these personnel are subsequently actively provid-
ing drug education to other health care professionals
based on the results of the intervention activities during
the period, and actively participating in the development
of standard clinical pathways.
Medicine is a rapidly growing field. However, the trad-
itional way of practicing medicine places too much bur-
den on doctors, preventing them from coping with the
rapidly developing environment as well as threatening
patient safety (Leape et al. 1999). Therefore, in devel-
oped countries, team-based treatment is becoming more
common and professionals in different fields, such as
pharmacists, nurses, and nutritionists, are cooperating
with each other, creating synergy as well as increasing
collaboration among clinical departments, which con-
tinuously highlights the importance of multidisciplinarytreatment. According to Peter et al., clinical pharmacists
are uniquely trained in therapeutics and provide com-
prehensive drug management of patients and provide
education about drug management to other health care
providers (Kaboli et al. 2006). Pharmacist intervention
outcomes include pharmacoeconomics, health-related
quality of life, patient satisfaction, medication appropri-
ateness, and adverse drug events. Therefore, to achieve
complete medication safety, pharmacists’ participation in
the treatment setting is essential, and if not permitted by
circumstances, at the very least, patients with relatively
severe illnesses should have the opportunity to receive a
wide range of prescription intervention activities by clin-
ical pharmacists. This is why pharmacists should be
present in the clinical setting in the current environment
to achieve optimum improvement in the quality of drug
treatment with overall quality of care.
Conclusion
The need for pharmacists’ prescription interventions
was high in the groups with long hospital stays and kid-
ney dysfunction among the ICU patients. The accept-
ance rate of pharmacist’ prescription interventions was
96.8%, and the intervention issue with the highest fre-
quency was related to drug dosage. Drugs with a high
frequency of intervention were antibiotics and antiulcer
drugs. Based on these results, we suggest that pharma-
cist’ prescription intervention should be started with pa-
tients who have relatively high disease severity. The
results could be utilized in countries which are planning
to develop pharmacists’ intervention service.
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– There is a positive impact on developing clinical
pharmacy services in intensive care unit.
– These practices may lead to a step-up in terms of
the quality of drug treatment in Korean hospitals.
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